Hoffman G S
Cleveland Clinic Foundation, Ohio, USA.
Rheum Dis Clin North Am. 1995 Feb;21(1):73-80.
About 20% of patients will have a monophasic, often self-limiting illness that does not require immunosuppressive therapy. Half of all patients that require corticosteroid therapy may achieve remission and discontinue medication without relapse. The other half of this group has glucocorticoid-resistant or relapsing disease, for which cytotoxic agents may induce remission or allow for disease control with lower doses of glucocorticoids. Although it is possible, it is desirable to distinguish those features of disease for which treatment is primarily best provided by immunosuppressive agents from those abnormalities that are due to critical vascular anatomic changes for which surgery or angioplasty are more appropriate.
约20%的患者会患单相性疾病,通常为自限性,无需免疫抑制治疗。所有需要皮质类固醇治疗的患者中,有一半可能实现缓解并停药且不再复发。这组患者中的另一半患有糖皮质激素抵抗或复发性疾病,对此细胞毒性药物可能诱导缓解或允许用较低剂量的糖皮质激素控制疾病。虽然有可能,但最好区分哪些疾病特征主要通过免疫抑制剂治疗效果最佳,哪些异常是由于关键血管解剖结构改变导致的,而手术或血管成形术对此更合适。